Biogen Earlier Highlighted Topline Results From Phase 2b Study Of Dapirolizumab Pegol In Systemic Lupus Erythematosus: Primary Endpoint Not Met, But Study Did Show Consistent, Potentially Meaningful Improvements For Majority Of Endpoints vs Placebo